GLOW vial label ingredients
The photographed GLOW Blend 70MG vial prints GLOW BLEND; 70MG; GHK-Cu 50MG / BPC-157 10MG; TB-500 10MG. These are component amounts on that particular label. They document what is printed, rather than independently verifying the contents or defining the similarly named pen. Label photograph.
The catalogue also lists the vial amount as 70MG. That field is not a concentration or a use instruction. For interpreting the science, the important next distinction is that the cited references concern separate components, with different substances, experimental settings and endpoints. GHK-Cu rat wound study, FDA BPC-157 assessment, FDA TB-500 assessment.
Research on the named components
For GHK-Cu, the 1993 study describes a copper complex of glycyl-L-histidyl-L-lysine. It compared the complex with saline in implanted wound chambers in rats and reported increased collagen and glycosaminoglycan content. Those are animal-chamber tissue measurements, not a human GLOW blend trial or a demonstration of cosmetic benefit from this vial. GHK-Cu rat wound study.
For BPC-157, FDA's July 2026 briefing identifies the evaluated free base as a 15-amino-acid fragment of BPC. In its human-evidence review, FDA found reported ulcerative-colitis enema data inadequate to support efficacy and safety for that use. It also distinguished the enema from a nominated rectal suppository. That is a specific formulation and evidence-adequacy assessment, not a positive finding for GLOW. FDA BPC-157 assessment.
For TB-500, FDA identifies an N-acetylated synthetic seven-amino-acid fragment of thymosin beta-4. It states that the pharmacological profile of non-acetylated LKKTETQ cannot be directly transferred to that material. The July 2026 review did not identify human clinical studies administering TB-500. Full-length thymosin beta-4 and differently modified fragments therefore cannot be used as equivalent evidence for this named component. FDA TB-500 assessment.
GLOW blend benefits and safety limits
The component references do not describe one shared experimental intervention: there is a rat wound chamber, a human enema report judged inadequate and a review that did not identify human TB-500 clinical studies. Putting three names on a label does not combine those findings into a clinical result, establish synergy or prove the listed blend performs as any component did in its own study. GHK-Cu rat wound study, FDA BPC-157 assessment, FDA TB-500 assessment, Label photograph.
FDA's GHK-Cu warning is specifically about compounded injectable products and potential immune-response risks related to aggregation and peptide impurities. Its BPC-157 communication separately identifies potential immune-response risks, peptide impurities and active-ingredient-characterization difficulties. These concerns retain their substance and route scopes; they are not test findings for this GLOW vial. FDA compounding safety communication.
GLOW vial versus pen
The GLOW pen is separately documented. The vial's component breakdown should remain attached to its own photographed label, rather than being assigned to another presentation from a similar GLOW name. For the vial, the useful conclusion is the literal three-component labeling plus the distinct limits of each component reference. Label photograph.
